Clinical Evidence

"The number one reason to deploy OLO was to reduce overhead cost. With OLO, we do not need to manage all the reagents, diluents and cleaning supplies, in addition to the quality control materials, which can be quite a lot of administrative work for a lean staff like ours. The real value is customer service, and Sight is just exceptional. It’s so far beyond anything I’ve seen in the industry."

"OLO’s performance is comparable to analyzers that are 50 times bigger and much more complicated to operate. The ability to take that much analytical power outside of the central lab and bring it to any setting where you can perform a CBC analysis in minutes has huge implications for hospital wards, such as oncology clinics, emergency rooms and beyond."

"To treat children in our urgent care centers, a CBC is essential. OLO represents a major innovation in our laboratories’ CBC analysis: low blood volume (finger-prick) sampling for a five-part differential with flagging. It’s a truly welcome development. At current volumes, we believe OLO could substantially reduce our costs."

"One of the main benefits of Sight OLO is that it’s easy to maintain. Because it has a cartridge-based system that stores all the reagents within a single cartridge, it doesn’t require buffer packs or calibrations that may require further maintenance. Sight OLO can both improve and expedite the treatment decision process for our healthcare providers."

"OLO has user friendly prompts for each step of the preparation so it’s impossible to go wrong. It even completes its own QC checks. It can be invaluable to have the patient's FBC within the consultation."

"The Sight OLO successfully completed a comprehensive evaluation study at the Sheba Tel Hashomer Medical Center. The evaluation compared OLO’s performances to a state-of-the-art analyzer and experienced microscopists, across a wide clinical range. OLO’s excellent performance exceeded predefined acceptance criteria in all aspects. Following the evaluation, we have started a research collaboration with the aim to explore the diagnostic potential of visual signatures in the blood images among different patient populations, including those with COVID-19."